New practice in semaglutide on type-2 diabetes and obesity: clinical evidence and expectation.
10.1007/s11684-021-0873-2
- Author:
Yalin LIU
1
;
Xianghang LUO
2
Author Information
1. Department of Endocrinology, Endocrinology Research Center, Xiangya Hospital of Central South University, Changsha, 410008, China.
2. Department of Endocrinology, Endocrinology Research Center, Xiangya Hospital of Central South University, Changsha, 410008, China. xianghangluo@hotmail.com.
- Publication Type:Review
- Keywords:
obesity;
semaglutide;
type 2 diabetes
- MeSH:
Diabetes Mellitus, Type 2/drug therapy*;
Glucagon-Like Peptide-1 Receptor/therapeutic use*;
Glucagon-Like Peptides;
Humans;
Hypoglycemic Agents/therapeutic use*;
Motivation;
Obesity/drug therapy*
- From:
Frontiers of Medicine
2022;16(1):17-24
- CountryChina
- Language:English
-
Abstract:
Obesity is an important risk factor of type 2 diabetes (T2D), which has become an important factor threatening human health. However, no perfect drug choice for obesity exists. Semaglutide is a kind of human glucagon-like peptide-1 (GLP-1) analog that promotes insulin secretion while inhibiting glucagon secretion through a glucose concentration-dependent mechanism. GLP-1 can also delay stomach emptying and suppress appetite to help lose weight. This review summarizes clinical evidence of the semaglutide effect on T2D and obesity and establishes expectations on future clinical trials for obesity treatment.
